8-K: MindMed Doses First Patient in Phase 3 Trial of MM120 for Major Depressive Disorder

MindMed has dosed the first patient in its Phase 3 Emerge study, evaluating MM120 ODT for the treatment of Major Depressive Disorder (MDD).

Summary

• MindMed has initiated its Phase 3 Emerge study to assess MM120 ODT (lysergide D-tartrate or LSD) for treating Major Depressive Disorder (MDD).
• The Emerge study is a 52-week trial divided into two parts: a 12-week double-blind, placebo-controlled study (Part A) and a 40-week open-label extension (Part B).
• Approximately 140 participants in the United States are expected to be enrolled in the Emerge study.
• The primary endpoint of Part A is the change from baseline in Montgomery-sberg Depression Rating Scale (MADRS) score at Week 6 between MM120 ODT 100 g and placebo.
• Topline data from the 12-week double-blind period is anticipated in the second half of 2026.
• The design and timing of a second MDD trial will be informed by the progress from Emerge and additional regulatory discussions.
• MM120 ODT is a proprietary, pharmaceutically optimized form of LSD using Catalent's Zydis ODT fast-dissolve technology.
• MindMed is also conducting Phase 3 trials (Voyage and Panorama) of MM120 ODT for Generalized Anxiety Disorder (GAD).
• In a Phase 2b study, MM120 showed clinically and statistically significant improvements in MADRS scores compared to placebo in patients with GAD.
• The FDA has granted Breakthrough Therapy Designation for the MM120 program in GAD.

Sentiment

Score: 7

Explanation: The announcement is positive, highlighting the initiation of a Phase 3 trial and previous positive results. However, the inherent risks associated with drug development and regulatory approval temper the overall sentiment.

Positives

• Initiation of Phase 3 Emerge study represents a significant step in the development of MM120 ODT for MDD.
• MM120 ODT has shown potential antidepressant effects in a Phase 2b study in GAD.
• The FDA has granted Breakthrough Therapy Designation for the MM120 program in GAD, potentially accelerating its development and review.
• The Innovation Passport granted by the U.K. MHRA may accelerate time to market and facilitate patient access to medicines in the U.K.

Risks

• The development of MM120 ODT is subject to risks associated with clinical studies, regulatory approval processes, and the novelty of the psychedelic-inspired medicines industry.
• The company has a history of negative cash flows and may incur future losses.
• Legislative and regulatory developments, including potential rescheduling of product candidates, could impact the ability to market MM120 ODT.
• The company faces risks associated with maintaining effective patent rights and other intellectual property protection.

Future Outlook

The company anticipates topline readout (Part A results) for the Phase 3 Emerge study of MM120 ODT in MDD in the second half of 2026 and plans to conduct a second Phase 3 study in MDD.

Management Comments

• Daniel R. Karlin, M.D., M.A., Chief Medical Officer of MindMed, stated that they are excited for the therapeutic potential that MM120 ODT shows for the 21 million people in the U.S. affected by MDD.
• Daniel R. Karlin, M.D., M.A., Chief Medical Officer of MindMed, stated that by running MDD and GAD Phase 3 studies concurrently, they can leverage the shared symptomatology between these conditions to more effectively match participants to the appropriate study based on their clinical presentation.
• Paul Summergrad, M.D., Professor of Psychiatry and Medicine at Tufts University School of Medicine and Chairman Emeritus of the department of psychiatry at Tufts Medical Center and a member of the MindMed Scientific Advisory Board, stated that the initiation of Emerge will allow the assessment of the potential of MM120 ODT in the treatment of MDD.

Industry Context

This announcement is significant in the context of the growing interest in psychedelic-inspired medicines for treating mental health disorders, particularly depression and anxiety, where existing treatments are often inadequate.

Comparison to Industry Standards

• The Phase 3 trial of MM120 ODT for MDD positions MindMed alongside other companies exploring psychedelic compounds for mental health, such as COMPASS Pathways (psilocybin) and Atai Life Sciences (various compounds).
• The use of LSD, a classic psychedelic, distinguishes MindMed's approach from companies focusing on psilocybin or MDMA.
• The Breakthrough Therapy Designation granted by the FDA is a positive signal, similar to designations received by other companies in the psychedelic medicine space, such as COMPASS Pathways for psilocybin in treatment-resistant depression.
• The 65% clinical response rate and 48% clinical remission rate sustained to Week 12 in the MM120 100 g cohort in the Phase 2b study for GAD are promising results, comparable to or exceeding response rates seen in some traditional antidepressant trials.

Stakeholder Impact

• Positive impact on patients with MDD who may benefit from a new treatment option.
• Potential positive impact on shareholders if the clinical trials are successful and the drug is approved.
• Potential positive impact on MindMed employees through company growth and success.

Next Steps

• Enrollment of approximately 140 participants in the Emerge study.
• Conducting Part A of the Emerge study, a 12-week double-blind, placebo-controlled study.
• Conducting Part B of the Emerge study, a 40-week open-label extension.
• Analyzing data from the Emerge study.
• Regulatory discussions to inform the design and timing of a second MDD trial.
• Anticipated topline readout (Part A results) for the Phase 3 Emerge study of MM120 ODT in MDD in the second half of 2026.

Key Dates

Keywords

MM120, Major Depressive Disorder, MDD, Phase 3, Emerge study, lysergide D-tartrate, LSD, MindMed, Clinical Trial, GAD, Generalized Anxiety Disorder, psychedelic medicine